DWA
NERV icon

Dorsey Wright & Associates’s Minerva Neurosciences NERV Stock Holding History

Dorsey Wright & Associates’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-170
Closed -$8K – 342
2020
Q1 		$8K Buy
+170
New +$10.3K ﹤0.01% 188

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dorsey Wright & Associates's NERV Position: Q2 2020 in Review

Dorsey Wright & Associates sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 170 shares — an estimated $8K sold.

Dorsey Wright & Associates first reported a position in NERV in Q1 2020 and held it in 1 quarter. The position peaked at $8K in Q1 2020. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • Dorsey Wright & Associates reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 170 Minerva Neurosciences shares in Q2 2020, an estimated $8K.
  • Dorsey Wright & Associates first reported a position in Minerva Neurosciences in Q1 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Minerva Neurosciences position peaked at $8K in Q1 2020.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Dorsey Wright & Associates's 13F filing for Q2 2020, filed 23 Jul 2020.